Back to Search Start Over

Podoplanin as an Attractive Target of CAR T Cell Therapy.

Authors :
Waseda, Masazumi
Kaneko, Shin
Source :
Cells (2073-4409). Sep2020, Vol. 9 Issue 9, p1971. 1p.
Publication Year :
2020

Abstract

To date, various kinds of cancer immunotherapy methods have been developed, but T cell immunotherapy is one of the most promising strategies. In general, T cell receptor (TCR) or chimeric antigen receptor (CAR) is used to modify the antigen specificity of T cells. CARs possess an underlying potential with treatment efficacy to treat a broad range of cancer patients compared with TCRs. Although a variety of CAR molecules have been developed so far, the clinical application for solid tumors is limited partly due to its adverse effect known as "on-target off-tumor toxicity". Therefore, it is very important for CAR T cell therapy to target specific antigens exclusively expressed by malignant cells. Here, we review the application of T cell immunotherapy using specific antigen receptor molecules and discuss the possibility of the clinical application of podoplanin-targeted CAR derived from a cancer-specific monoclonal antibody (CasMab). [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
20734409
Volume :
9
Issue :
9
Database :
Academic Search Index
Journal :
Cells (2073-4409)
Publication Type :
Academic Journal
Accession number :
146142863
Full Text :
https://doi.org/10.3390/cells9091971